Saxenda overview
Brand name for liraglutide 3.0 mg daily, FDA-approved for chronic weight management.
Saxenda at a glance
Manufacturer
Novo Nordisk
FDA status
FDA-approved
Related pages
- Clinical research overview
- Compare GLP-1 forms
- Compounded vs brand
- NexLife (highest v4.1 score)
Key facts, checked November 20, 2026
The Saxenda label (effective February 25, 2026) covers weight management in adults and in patients 12 and older weighing more than 60 kg with obesity, as a once-daily injection alongside diet and activity. In the liraglutide adolescent trial (NEJM 2020), BMI fell 4.64 percentage points more with liraglutide than with placebo over 56 weeks, and rose again after the drug was stopped. FDA drug-shortage data (openFDA) list liraglutide injection as in shortage. Medicare’s GLP-1 Bridge covers Foundayo, Wegovy and the Zepbound KwikPen, not Saxenda.